



Alexion Announces €100 Million Investment in Athlone Site With Construction of New Manufacturing Facility

Alexion Pharmaceuticals today announced an additional €100 million investment in an expansion of its Athlone operations which will result in the creation of 50 additional jobs bringing total employment at the facility to greater than 100 people. The investment will see the construction of a new biologics manufacturing facility at the site.

“Alexion is delighted to announce this additional expansion to our existing Athlone site as we deliver upon our mission to transform the lives of patients with ultra-rare diseases,” said Julie O’Neill, Executive Vice President, Global Operations, at Alexion. “Ireland is a key location for Alexion’s global operations and we are committed to further developing our manufacturing facilities in the country to support increasing production needs of our highly innovative and life-transforming therapies.”

The new manufacturing facility demonstrates Alexion’s continued commitment to Ireland and to Athlone since first announcing a presence in the area in 2014. The current Athlone site houses a vial fill-finish facility. Alexion is also currently constructing a large-scale bulk biologics manufacturing facility at its Dublin site in College Park. Between its facilities in Athlone and College Park, Alexion currently employs over 250 people in Ireland, and expects to continue to grow to almost 500 employees by the end of 2019. Alexion has announced investments totalling €600 million in Ireland since 2013.

“This additional investment also demonstrates our commitment to job growth in Ireland and the Athlone region, as we look to hire the best talent locally as part of this site expansion,” said Grainne McAleese, General Manager, Alexion Ireland. “Alexion is at the forefront of innovation and all our staff are passionate about our commitment to the patients we serve. We already have a well-established presence in Athlone since 2014, with a great local workforce, and we are very firmly committed to this region going forward. We are establishing collaborations with local schools and institutes of technology and will be offering excellent career opportunities for people in the area.”

About Alexion

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed and commercialises the first and only approved complement inhibitor to treat patients with two life-threatening ultra-rare disorders – paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS). As the global leader in complement inhibition, Alexion is strengthening and broadening its portfolio of complement inhibitors, including evaluating potential indications for additional severe and ultra-rare disorders. Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). In addition, Alexion is advancing the most robust rare disease pipeline in the biotech industry, with highly innovative product candidates in multiple therapeutic areas. Further information about Alexion can be found at: www.alexionpharma.eu or www.alexionpharma.ie